Company intelligence / Profile preview

Esanex, Inc.

Indianapolis, Indiana, United Statespmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Phase 2

Overview

Esanex, Inc. developed highly selective oral Hsp90 inhibitors for oncology indications. Its lead asset SNX‑5422 advanced through multiple Phase 1 studies in solid tumors and hematologic malignancies such as CLL. The most recent known trial combined SNX‑5422 with the BTK inhibitor ibrutinib to address residual disease in CLL patients but was terminated. Earlier studies explored combinations with standard chemotherapies in lung cancer. There are no reported late-stage or commercial programs.

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

snx-5422

Partnerships

Collaborated with academic centers such as The Ohio State University for clinical trials[6]. No major pharma partnerships disclosed.

Beyond the preview

Go deeper on Esanex, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Esanex, Inc..

Explore the full profile